PHVS (Pharvaris NV) Stock Based Compensation: $23.05 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHVS Pharvaris NV PHVS
22 GF Score
Price $34.30
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Stock Based Compensation?

Pharvaris NV PHVS -2.11% 22 Stock Based Compensation is $23.05 Mil as of Mar. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Pharvaris NV's Stock Based Compensation for the three months ended in Mar. 2026 was $5.66 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $23.05 Mil.

Pharvaris NV Stock Based Compensation Related Terms

Pharvaris NV Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV Stock Based Compensation Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 9.26 12.02 11.63 16.97 22.31

Pharvaris NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.46 6.34 5.74 5.31 5.66
PHVS
22GF Score
Pharvaris NV PHVS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.05 Mil.

What does a Stock Based Compensation of $23.05 Mil mean?
Pharvaris NV (PHVS) has a Stock Based Compensation of $23.05 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pharvaris NV and its competitors.
Is Pharvaris NV's Stock Based Compensation too high?
Pharvaris NV's current Stock Based Compensation is $23.05 Mil. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Stock Based Compensation compare to BHVN and NRIX?
Pharvaris NV's Stock Based Compensation of $23.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pharvaris NV and its competitors. Pharvaris NV's current Stock Based Compensation is $23.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current Stock Based Compensation of $23.05 Mil. The current Stock Based Compensation is $23.05 Mil. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current Stock Based Compensation is $23.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.30
Price